MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.
MagicMed’s molecular derivatives library, the Psybrary™ is anticipated to be an essential building block from which industry can develop new patented products.
The initial focus of the Psybrary™ is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, ibogaine, mescaline, and ayahuasca.
creating a psychedelic derivatives library
MagicMed scientists start with a natural psychedelic molecule such as psilocybin and modify its structure to create many new derivative variant molecules which will form part of the MagicMed Psybrary™.
The proprietary scientific tools MagicMed employs for its derivatizations are trade secrets developed in-house from our decades of research and development in the field of natural product biochemistry.
Natural molecules such as psilocybin cannot be patented as a molecular composition. New molecular derivative compositions in the PsybraryTM are patentable as are MagicMed’s proprietary methods of manufacturing the derivatives within the Psybrary™.
working with an industry partner
MagicMed partners will be able to search, select and test from the derivatives in the Psybrary™ and use them as a building block for their own product development based on the indication that they are targeting (anxiety, depression, addiction, PTSD and many others).
The MagicMed team will then continue to work with its partners to further define and improve upon their selected derivative molecules to create finished medicinal product candidates and, in future, licit consumer products.
creating an end product
Once developed and approved, our Industry partners will sell products into medical and licit consumer markets.
MagicMed’s partners potentially gain a significant edge over their competitors in new product development based on Psybrary™ molecules that are fully patent protected.
We will work with partners post-development to monitor the market progress of the products produced in partnership with us to help them to continuously improve and expand.
DR. JOSEPH TUCKER
Dr. Joseph Tucker is a seasoned executive who has built several publicly traded biotechnology companies. He has worked closely with the MagicMed Science team since 2013. As CEO of MagicMed Industries, Dr. Tucker focuses on partnership development, capital raising and the pursuit of a successful exit strategy.
DR. JILLIAN HAGEL
Dr. Jillian Hagel has previously held COO and Vice President roles in the biotechnology industry. She focuses on Science team coordination and patent filings. Dr. Hagel will lead the Science team’s laser focus on delivering partner milestones.
DR. PETER FACCHINI
Dr. Peter Facchini has previously held the Chief Scientific Officer role at other publicly-traded and private biotechnology companies. A recognized leader in the development of new molecular derivatives, Dr. Facchini has published more than 160 scientific papers and holds 20 patents in the field. At MagicMed Industries Dr. Facchini is applying his focus to the creation and patenting of psychedelics-derivatives.
MagicMed Industries Inc.
3655 – 36 Street NW
Calgary, AB T2L 1Y8